Ramaphosa's energy plan Webinar banner

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

BioNTech CEO says new Covid-19 vaccines will be needed...



BioNTech CEO says new Covid-19 vaccines will be needed in 2022

A health worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine inside the Discovery Ltd. mass vaccination site at the Cape Town International Convention Centre in Cape Town, South Africa, on Tuesday, Sept. 7, 2021. Photographer: Dwayne Senior/Bloomberg
By Bloomberg
04 Oct 2021 0

(Bloomberg) --The head of BioNTech SE, the German company that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus.

By Fareed Sahloul
Oct 3, 2021, 1:39 PM
Word Count: 164

Ugur Sahin, co-founder and chief executive officer of BioNtech, told the Financial Times that while current variants of Covid-19, such as the contagious delta strain, were not different enough to undermine current vaccinations, new strains will emerge that can evade booster shots and the body’s immune defenses.

“This year [a different vaccine] is completely unneeded, but by mid-next year, it could be a different situation,” he said. “This is a continuous evolution, and that evolution has just started.”

BioNTech partnered with U.S. pharmaceuticals giant Pfizer Inc. to develop its Covid-19 vaccine. Last month, the companies submitted initial data to U.S. regulators about the use of the vaccine in children aged 5 to 11, one step closer to bringing shots to school-age kids.

© 2021 Bloomberg L.P.

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]


Please peer review 3 community comments before your comment can be posted